Press Releases

All
By Year

Dec. 18, 2023

Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomfort

Apr. 20, 2023

Azura Ophthalmics to Present New Data on AZR-MD-001 in Meibomian Gland Dysfunction at American Society of Cataract and Refractive Surgery and Association for Research in Vision and Ophthalmology Annual Meetings

Jan. 17, 2023
Azura Ophthalmics Announces Participation at the 2023 SVB Securities Global Biopharma Conference

Dec. 9, 2022

Azura Ophthalmics Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction at Ophthalmology Innovation Summit XII

Nov. 21, 2022

Azura Ophthalmics Announces Participation at Upcoming Investor Conferences

Nov. 17, 2022

Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction
Oct. 19, 2022
Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
Sep. 28, 2022
Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction

Sep. 21, 2022

Azura Ophthalmics Announces Formation of Scientific Advisory Board (SAB)
Sep. 7, 2022
Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision Quality Related to Contact Lens Discomfort
Sep. 7, 2021
Azura Ophthalmics Appoints Biopharma Industry Veteran Steven Altschuler, M.D. as Chair of the Board
Mar. 3, 2021
Azura Ophthalmics Announces Positive Topline Results from Phase 2 Program of the Company’s Investigational Treatment for Meibomian Gland Dysfunction
Dec. 21 2020
Azura Ophthalmics Announces Primary Endpoints Met in Topline Results from Phase 2 Trial of the Company’s Investigational Treatment for Contact Lens Discomfort
Oct. 22, 2020
Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease
Oct. 10, 2017
Azura Ophthalmics Receives $16 Million in Series B Funding to Develop Treatment for Leading Cause of Dry Eye Disease

Dec. 18, 2023

Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomfort

Apr. 20, 2023

Azura Ophthalmics to Present New Data on AZR-MD-001 in Meibomian Gland Dysfunction at American Society of Cataract and Refractive Surgery and Association for Research in Vision and Ophthalmology Annual Meetings

Jan. 17, 2023
Azura Ophthalmics Announces Participation at the 2023 SVB Securities Global Biopharma Conference

Dec. 9, 2022

Azura Ophthalmics Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction at Ophthalmology Innovation Summit XII

Nov. 21, 2022

Azura Ophthalmics Announces Participation at Upcoming Investor Conferences

Nov. 17, 2022

Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction
Oct. 19, 2022
Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
Sep. 28, 2022
Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction

Sep. 21, 2022

Azura Ophthalmics Announces Formation of Scientific Advisory Board (SAB)
Sep. 7, 2022
Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision Quality Related to Contact Lens Discomfort
Sep. 7, 2021
Azura Ophthalmics Appoints Biopharma Industry Veteran Steven Altschuler, M.D. as Chair of the Board
Mar. 3, 2021
Azura Ophthalmics Announces Positive Topline Results from Phase 2 Program of the Company’s Investigational Treatment for Meibomian Gland Dysfunction
Events
Upcoming
Past
Nov. 29 – Dec. 1, 2022
Piper Sandler 34th Annual Healthcare Conference
Dec. 2-3, 2022
San Diego, CA
Ophthalmology Innovation Summit XII (OIS)
Jan. 9-12, 2023
San Francisco, CA
JP Morgan Healthcare Conference
Jan. 14-20, 2023
Hawaiian Eye and Retina 2023
Media
Oct. 22, 2020
Azura Ophthalmics gets a $20M boost for its R&D work on eye diseases
Scroll to Top